Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Interpace Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $594.00K, down 19.9% year over year. For fiscal 2025 it was $642.00K, down 5.0% from the year before. Over ten years it grew -11.9% a year on average. The highest annual figure on record is $2.81M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $642.00K | -5.0% |
| FY2024 | Dec 31, 2024 | $676.00K | +6.3% |
| FY2023 | Dec 31, 2023 | $636.00K | -9.5% |
| FY2022 | Dec 31, 2022 | $703.00K | -52.9% |
| FY2021 | Dec 31, 2021 | $1.49M | -46.6% |
| FY2020 | Dec 31, 2020 | $2.80M | -0.5% |
| FY2019 | Dec 31, 2019 | $2.81M | +32.3% |
| FY2018 | Dec 31, 2018 | $2.12M | +45.4% |
| FY2017 | Dec 31, 2017 | $1.46M | -11.3% |
| FY2016 | Dec 31, 2016 | $1.65M | -28.1% |
| FY2015 | Dec 31, 2015 | $2.29M | +798.8% |
| FY2014 | Dec 31, 2014 | $255.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $149.00K | -13.9% |
| Q1 FY2026 | Mar 31, 2026 | $153.00K | -13.6% |
| Q4 FY2025 | Dec 31, 2025 | $142.00K | -26.4% |
| Q3 FY2025 | Sep 30, 2025 | $150.00K | -24.6% |
| Q2 FY2025 | Jun 30, 2025 | $173.00K | +18.5% |
| Q1 FY2025 | Mar 31, 2025 | $177.00K | +29.2% |
| Q4 FY2024 | Dec 31, 2024 | $193.00K | +27.0% |
| Q3 FY2024 | Sep 30, 2024 | $199.00K | +33.6% |
| Q2 FY2024 | Jun 30, 2024 | $146.00K | -21.5% |
| Q1 FY2024 | Mar 31, 2024 | $137.00K | -8.1% |
| Q4 FY2023 | Dec 31, 2023 | $152.00K | +97.4% |
| Q3 FY2023 | Sep 30, 2023 | $149.00K | -22.0% |
| Q2 FY2023 | Jun 30, 2023 | $186.00K | -8.8% |
| Q1 FY2023 | Mar 31, 2023 | $149.00K | -35.5% |
| Q4 FY2022 | Dec 31, 2022 | $77.00K | -75.6% |
| Q3 FY2022 | Sep 30, 2022 | $191.00K | -40.7% |
| Q2 FY2022 | Jun 30, 2022 | $204.00K | -51.9% |
| Q1 FY2022 | Mar 31, 2022 | $231.00K | -63.7% |
| Q4 FY2021 | Dec 31, 2021 | $315.00K | -53.1% |
| Q3 FY2021 | Sep 30, 2021 | $322.00K | -57.8% |
| Q2 FY2021 | Jun 30, 2021 | $424.00K | -22.9% |
| Q1 FY2021 | Mar 31, 2021 | $637.00K | -21.3% |
| Q4 FY2020 | Dec 31, 2020 | $672.00K | -13.6% |
| Q3 FY2020 | Sep 30, 2020 | $763.00K | -11.0% |
| Q2 FY2020 | Jun 30, 2020 | $550.00K | -15.0% |
| Q1 FY2020 | Mar 31, 2020 | $809.00K | +53.2% |
| Q4 FY2019 | Dec 31, 2019 | $778.00K | +30.5% |
| Q3 FY2019 | Sep 30, 2019 | $857.00K | +68.0% |
| Q2 FY2019 | Jun 30, 2019 | $647.00K | +24.9% |
| Q1 FY2019 | Mar 31, 2019 | $528.00K | +5.4% |
| Q4 FY2018 | Dec 31, 2018 | $596.00K | +130.1% |
| Q3 FY2018 | Sep 30, 2018 | $510.00K | +5.6% |
| Q2 FY2018 | Jun 30, 2018 | $518.00K | +25.4% |
| Q1 FY2018 | Mar 31, 2018 | $501.00K | +63.7% |
| Q4 FY2017 | Dec 31, 2017 | $259.00K | -15.9% |
| Q3 FY2017 | Sep 30, 2017 | $483.00K | -26.7% |
| Q2 FY2017 | Jun 30, 2017 | $413.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $306.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $308.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $659.00K | – |
See a number that looks wrong?